• Explore /
  • Poster
  • / SWOG S1115: Randomized phase II trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in pretreated patients (Pts) with metastatic pancreatic cancer.

SWOG S1115: Randomized phase II trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in pretreated patients (Pts) with metastatic pancreatic cancer.

Abstract Poster

Authors

null

Vincent M. Chung

City of Hope, Duarte, CA

Vincent M. Chung , Shannon L McDonough , Philip Agop Philip , Dana Backlund Cardin , Andrea Wang-Gillam , Laifong Hui , Andrew M. Lowy , Katherine Guthrie , Charles David Blanke , Howard S. Hochster

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT01658943

Citation

J Clin Oncol 33, 2015 (suppl; abstr 4119)

DOI

10.1200/jco.2015.33.15_suppl.4119

Abstract #

4119

Poster Bd #

231

Abstract Disclosures

Similar Posters

First Author: Vincent M. Chung

Poster

2017 Gastrointestinal Cancers Symposium

5-fluorouracil, oxaliplatin and dasatinib (FOLFOX-D) for previously untreated metastatic pancreatic adenocarcinoma.

5-fluorouracil, oxaliplatin and dasatinib (FOLFOX-D) for previously untreated metastatic pancreatic adenocarcinoma.

First Author: Thomas J. George Jr.

First Author: Jean-Luc Van Laethem

First Author: Ana De Jesus-Acosta